United Kingdom· GB-APID-40990311000001102
Vyepti 100mg/1ml concentrate for solution for infusion vials
A eptinezumab product containing eptinezumab, registered in United Kingdom by Lundbeck Ltd. The same ATC class is registered in 14 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Eptinezumab is registered in 14 of 19 countries.
Countries holding a registration under ATC N02CD05 (eptinezumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Eptinezumab · ATC N02CD05
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Eptinezumab
- Manufacturer
- Lundbeck Ltd
- Country
- United Kingdom (GB)
- ATC code
- N02CD05
- ATC class
- Eptinezumab
- Defined daily dose
- 1.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin5702150154170
- gtin05702150154019
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Eptinezumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainVYEPTI 100 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONH. Lundbeck A/S
- FinlandVYEPTIH. Lundbeck A/S
- CzechiaVYEPTIH. Lundbeck A/S, Valby
- United StatesVyeptiLundbeck Pharmaceuticals LLC
- BelgiumVyepti 100 mgH. Lundbeck
- IcelandVyeptiH. Lundbeck A/S*
- NetherlandsVyepti 100 mg/ml, concentraat voor oplossing voor infusieH. Lundbeck A/S
- NorwayVyeptiH. Lundbeck A/S
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Vyepti
- Norway · Vyepti
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6a533a05-e27d-47c3-8cc0-569c5c7cc975 GET /v1/drugs/6a533a05-e27d-47c3-8cc0-569c5c7cc975?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "40990311000001102",
"desc": "Vyepti 100mg/1ml concentrate for solution for infusion vials (Lundbeck Ltd)",
"form": "Solution for infusion",
"vpid": "41010711000001103",
"source": "dmd",
"vtm_id": "871788009",
"strength": "100 mg",
"substance": "Eptinezumab",
"ingredient": "Eptinezumab",
"supplier_code": "2075801000001108"
}See everything about eptinezumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.